Pfizer

Pfizer front runner to clinch Strides Arcolab’s specialty biz for $1.7B

30 August, 2012

Global pharmaceutical manufacturer Pfizer is in advanced talks with Strides Arcolab to buy its specialty business housing injectable drug unit for $1.7 billion (Rs 9,460 crore), three people with knowledge of the development told VCCircle. This would be the third largest M&A deal in the pharmaceutical sector in India, behind Daiichi Sankyo’s acquisition of majority stake in Ranbaxy and Abbott Laboratories’ purchase of the domestic formulations business of Piramal Healthcare.


Leave Your Comment
Strides Arcolab promoters may sell their entire stake for $540M, Pfizer front-runner

Strides Arcolab promoters may sell their entire stake for $540M, Pfizer front-runner

Pooja Sarkar 5 years ago
Promoters of Strides Arcolab Ltd, who were earlier involved in negotiations for selling the injectables business of the public listed company, are now also looking...
Strides Arcolab buying Shasun Pharma in all stock deal worth over $221M

Strides Arcolab buying Shasun Pharma in all stock deal worth over $221M

Jasleen Kaur Batra 3 years ago
Bangalore-based Strides Arcolab Ltd, which sold its injectable-medicine unit Agila Specialties for $1.65 billion to Mylan, has struck a deal to buy small drug maker...
Strides Arcolab Buys Star Drugs’ Sterile Formulations Plant For $23.8M

Strides Arcolab Buys Star Drugs’ Sterile Formulations Plant For $23.8M

Bhawna Gupta 1 year ago
Strides Arcolab Ltd has acquired a US FDA approved sterile formulations facility from another Bangalore-based pharmaceutical company Star Drugs and Research Labs Ltd (SDRL) for...
No Comments

Pfizer front runner to clinch Strides Arcolab’s specialty biz for $1.7B

Powered by WordPress.com VIP